drugset / Trial / NCT06698250
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will investigate if modulating the tumor microenvironment with biologic agents like XL-092 will have synergistic effect when combined with checkpoint based immunotherapeutic treatment of patients with hepatocellular carcinoma (HCC).
Timeline
- Start
- 2024-12-18
- Primary completion
- 2026-12-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | 300 mg | Intravenous |
| Subject | Zanzalintinib | Small molecule | 40 mg | Oral |
| Subject | Zanzalintinib | Small molecule | 60 mg | Oral |